Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shemin

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Transplantation|June 14, 2000
Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patientsA G Bostom, D Shemin, R Y Gohh, et al.
Atherosclerosis|February 1, 1995
Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementationA G Bostom, D Shemin, M R Nadeau, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 21, 1999
Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis--role of haemodialysis treatmentR Chodock, E Mylonakis, D Shemin, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 31, 1997
Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective studyA G Bostom, D Shemin, P Verhoef, et al.
Advances in Renal Replacement Therapy|October 29, 2000
First hemodialysis access selection varies with patient acuityA L Friedman, C Walworth, C Meehan, et al.
Circulation|June 22, 2000
Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patientsA G Bostom, D Shemin, P Bagley, et al.
Kidney International. Supplement|February 13, 2001
Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipientsA G Bostom, D Shemin, R Y Gohh, et al.
Kidney International|January 1, 1996
High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patientsA G Bostom, D Shemin, K L Lapane, et al.
Atherosclerosis|April 7, 1995
Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyA G Bostom, D Shemin, K L Lapane, et al.
Atherosclerosis|June 1, 1996
Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patientsA G Bostom, D Shemin, K L Lapane, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Transplantation|June 14, 2000
Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patientsA G Bostom, D Shemin, R Y Gohh, et al.
Atherosclerosis|February 1, 1995
Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementationA G Bostom, D Shemin, M R Nadeau, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 21, 1999
Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis--role of haemodialysis treatmentR Chodock, E Mylonakis, D Shemin, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 31, 1997
Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective studyA G Bostom, D Shemin, P Verhoef, et al.
Advances in Renal Replacement Therapy|October 29, 2000
First hemodialysis access selection varies with patient acuityA L Friedman, C Walworth, C Meehan, et al.
Circulation|June 22, 2000
Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patientsA G Bostom, D Shemin, P Bagley, et al.
Kidney International. Supplement|February 13, 2001
Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipientsA G Bostom, D Shemin, R Y Gohh, et al.
Kidney International|January 1, 1996
High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patientsA G Bostom, D Shemin, K L Lapane, et al.
Atherosclerosis|April 7, 1995
Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyA G Bostom, D Shemin, K L Lapane, et al.
Atherosclerosis|June 1, 1996
Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patientsA G Bostom, D Shemin, K L Lapane, et al.
Pageof 7